News Articles for NeuroScientific Biopharmaceuticals

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In
NEUROSCIENTIFIC NSB BNBWA Bulls N' Bears 26 May 2026

NeuroScientific hails 80% clinical response in Crohn’s stem cell program

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

NeuroScientific Biopharmaceuticals has reported strong clinical outcomes from its StemSmart stem cell therapy, with four of five patients with fistulising Crohn's disease achieving a clinical response and all showing improvement. The results build on earlier patient data and will help guide a planned phase two trial as the company continues its push towards commercial development.

NEUROSCIENTIFIC_Q-GEN_BNBWA Bulls N' Bears 17 Mar 2026

NeuroScientific readies stem cell supply boost for bowel disease trials

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

NeuroScientific Biopharmaceuticals has taken a major step towards scaling up its StemSmart stem cell therapy by launching its first manufacturing run with Australian cell therapy specialist Q-Gen. The milestone signals the start of transferring the company's patented production process to a clinical-scale facility capable of supplying future trials and potentially, commercial demand.

NEUROSCIENTIFIC_CROHNS_BNBWA Bulls N' Bears 13 Jan 2026

NeuroScientific Biopharmaceuticals soars on stem cell tech results

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Early-stage biotech NeuroScientific Biopharmaceuticals has delivered real-world promise for those living with chronic Crohn's disease following recent findings from its StemSmart cell therapy. Prescribed under Australia's Special Access Scheme, the results showed a strong clinical response in some of Crohn's disease's toughest patients, giving the company valuable validation, sharper trial design and a clearer pathway into a multi-billion-dollar global market.

NEUROSCIENTIFIC_NATHAN SMITH_BULLSNBEARWA Bulls N' Bears 11 Nov 2025

NeuroScientific widens chronic bowel disease stem cell therapy program

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

NeuroScientific Biopharmaceuticals has reached another clinical milestone, with a fourth Crohn's disease patient now receiving its patented StemSmart stem cell therapy for the chronic bowel disease under Australia's Special Access Scheme. The company says data from the real-world program will directly inform the design of its upcoming phase two trial, slated to begin in the second half of 2026.

NEUROSCIENTIFIC_KIDNEY TRANSPLANT_BULLSNBEARSWA Bulls N' Bears 27 Aug 2025

NeuroScientific stem cell studies show kidney transplant promise

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

NeuroScientific Biopharmaceuticals has unveiled positive results from two studies using its stem cell therapy in kidney transplantation. Eight out of 10 patients in a small case series, facing severe organ rejection, retained their donor kidney. A second study showed the treatment was safe and may improve graft function in deceased-donor transplants. The findings have bolstered the company's plans for a wider clinical development in the multibillion-dollar global market.

NeuroScientific-Biopharmaceuticals-STEMSMART_BULLSNBEARSWA Bulls N' Bears 31 Jul 2025

NeuroScientific locks in deal to scale-up stem cell production

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals is transferring its patented StemSmart technology to one of Australia's biggest and most experienced manufacturers to scale up clinical-grade production, ahead of the commercialisation of its infusion therapy for hard-to-treat conditions, starting with Crohn's disease. Queensland-based Q-Gen Cell Therapeutics specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control.

NEUROSCIENTIFIC_NATHAN SMITH_BULLSNBEARWA Bulls N' Bears 28 Jul 2025

Strategic CEO hire to drive NeuroScientific stem cell therapy release

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Melbourne executive Nathan Smith will take the reins as CEO at NeuroScientific Biopharmaceuticals, bringing his strategic and commercial nous as the company gears up to release its innovative StemSmart stem cell technology. This is the Perth-based biotech's second heavy-hitting appointment, after it recruited a well-credentialled chief medical officer in Perth-based paediatric haematologist and oncologist Dr Catherine Cole.

NEUROSCIENTIFIC_CATHY COLE_BULLSNBEARSWA (1) Bulls N' Bears 25 Jul 2025

NeuroScientific appoints top doctor ahead of stem cell therapy rollout

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

NeuroScientific Biopharmaceuticals has snagged a well-credentialled WA haematologist and oncologist as its chief medical officer. The company is banking on Dr Catherine Cole's decades of clinical leadership and trials experience to help it roll out its innovative stem cell therapy. A trial is underway to test its stem cell technology to treat patients with a difficult-to-treat complication of Crohn's disease.

BNBs_ASX Runners of the Week Bulls N' Bears 17 Apr 2025

ASX Runners: Grand Gulf, Meteoric, Aus Strategic Materials & NeuroScientific

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

This week's Bulls N' Bears ASX Runner of the Week is… Grand Gulf Energy, after it acquired an option over a billion-barrel oil prospect off the coast of Namibia. Meteoric Resources announced a maiden resource for its ionic clay deposit in Brazil, Aus Strategic Materials flourished under US rare earths supply concerns following Chinese export bans and NeuroScientific Biophamaceuticals acquired an innovative and life-changing stem cell technology company.

Appointments 01 Dec 2023

Board Moves December 1, 2023

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Our board moves wrap includes Dianne Angus, Geoff Pocock, Andrew Chapman, Tod McGrouther, Gaurav Gupta, Mark Licciardo, Joel Ives, Karen Logan, Joan Dabon, Harry Spindler, Dan Robinson, Stephen Parker, Ross Walker, Stephen Carter, Grant Lukey, Rhett Morson, Bruce Rathie, Alec PIsmiris, Geoff Stalley, Kenneth Hall, Cathy Moises, and Brady Hall.

X